STOCK TITAN

Vireo Growth Inc Stock Price, News & Analysis

VREOF OTC

Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.

Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.

Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.

Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.

Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.

Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.

Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) announced a strategic partnership with Ace Venture of NY to create New York’s first scaled, minority-owned, vertically integrated medical cannabis operator.

Under the agreement, Ace will acquire a 51% ownership interest in Vireo Health of New York, while Vireo will continue providing operational and compliance support.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) closed its acquisition of Eaze Inc. on April 1, 2026, expanding operations into California and Florida and increasing scale across existing markets.

The transaction expands Vireo’s footprint to 10 states with over 160 dispensaries and approximately 800,000 sq. ft. of cultivation and production, adds Eaze’s 67 retail locations and its delivery platform (over 12 million deliveries), and contributes an incremental 15 Colorado dispensaries. Cory Azzalino will lead Vireo’s California business as CEO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
-
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) said its Management Services Agreement with PharmaCann became effective on March 22, 2026, allowing Vireo to manage specified PharmaCann retail assets in Colorado until closing.

Under the Asset Purchase Agreement, Vireo delivered 90,740,741 subordinate voting shares from treasury into escrow with Odyssey Trust Company; those shares will remain in escrow until release at closing, which is expected in Q2 2026 and remains subject to regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) updated a nonbinding MOU to acquire Hawthorne from ScottsMiracle-Gro, targeting completion after five business days and planning a share-based transaction in Q2 2026.

The contemplated deal includes US$35M cash, ~US$50M net working capital, ~US$20M inventory, issuance of 206M shares and warrants for 80M shares exercisable at US$0.85 for five years; appointment of Chris Hagedorn to Vireo’s board is planned upon closing and shareholder approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary

Vireo Growth (CSE: VREO; OTCQX: VREOF) closed its acquisition of certain Schwazze assets on March 24, 2026, acquiring 45 dispensaries (24 in Colorado, 21 in New Mexico) and one manufacturing facility in each state at an assumed share price of $0.661.

The transaction implies an estimated valuation of under 4x pro forma EBITDA. Justin Dye will become chairman of the Colorado and New Mexico business and Forrest Hoffmaster will be CEO of that regional business. Management cites a potential long‑term retail footprint of over 75 dispensaries, subject to approvals and capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) reported Q4 FY2025 GAAP revenue of $104.5M, up 317.7% YoY, driven by recent M&A activity. Pro forma Q4 revenue was $104.5M (26.1% above pro forma prior-year). Q4 cash was $122.5M, and multiple Colorado retail acquisitions plus an MOU for Hawthorne are expected to close in H1 2026.

Q4 adjusted EBITDA was $29.5M (28.2% margin); same-store sales ex-Minnesota rose 11.3% YoY, and wholesale increased 55% YoY.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) will release fourth quarter and full year 2025 financial results on Tuesday, March 17, 2026, before market open. Management will host a conference call the same day at 8:00 a.m. ET (7:00 a.m. CT) to discuss results and answer investor questions.

Dial-in details: 1-800-715-9871 (US/Canada) or 1-646-307-1963 (International), conference ID 9471311. A live audio webcast will be available in the company’s Investor Relations Events & Presentations section at the provided Q4 events link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
earnings date
-
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) entered a nonbinding MOU to acquire The Hawthorne Gardening Company from ScottsMiracle-Gro in a planned share-based transaction expected to close in the first fiscal quarter of 2026. Vireo intends to appoint Chris Hagedorn to its board upon completion, and Scotts will transition to an equity participation arrangement.

The proposed deal brings Hawthorne's indoor and hydroponic gardening platform into Vireo's operations and deepens collaboration with Scotts while subject to customary closing conditions and final documentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
-
Rhea-AI Summary

Vireo Growth (OTCQX: VREOF) agreed to acquire Eaze Inc., adding operations in California, Florida and expanding in Colorado. The deal expands Vireo’s footprint to 10 states with 166 dispensaries and about 800,000 sq. ft. of cultivation and production.

Eaze operates 65 active retail locations, has completed over 12 million deliveries, and brings delivery coverage across major California metros and 39 Florida stores with ~64,000 sq. ft. canopy. Consideration is ~$47.0M paid as ~84 million subordinate voting shares at a deemed price of US$0.56, with an earn-out potential tied to 3.84x adjusted EBITDA payable in shares (floor price $1.05 or VWAP). Closing is expected in H1 2026 and remains subject to customary approvals and closing adjustments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
Rhea-AI Summary

Vireo Growth (CSE: VREO; OTCQX: VREOF) announced it will acquire additional outstanding senior secured convertible notes of Medicine Man Technologies (dba Schwazze).

The notes have approximately $2.6 million principal plus accrued interest and will be purchased at a substantial discount for approximately $1.6 million payable in subordinate voting shares at $0.54 per share. Upon closing, expected later this month, Vireo will hold about 89% of outstanding senior secured convertible notes of Schwazze. Completion is subject to customary conditions and approvals. The share consideration will be subject to Canadian resale restrictions and CSE hold periods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags

FAQ

What is the current stock price of Vireo Growth (VREOF)?

The current stock price of Vireo Growth (VREOF) is $0.4 as of April 2, 2026.

What is the market cap of Vireo Growth (VREOF)?

The market cap of Vireo Growth (VREOF) is approximately 435.5M.

VREOF Rankings

VREOF Stock Data

435.51M
771.70M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Minneapolis

VREOF RSS Feed